Table 3.
Significant associations of CRHR2 genotypes and acute bronchodilator response in CAMP and replication cohorts
| CAMP | SEPRACOR | LODO | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variants | Count (freq) | mean (se) | p-value | Count (freq) | mean (se) | p-value | Count (freq) | mean (se) | p-value |
| rs255100 | |||||||||
| TT | 221 (0.36) | 11.70 (0.54) | 0.02 | 151 (0.35) | 40.49 (2.33) | 0.78 | 61 (0.40) | 11.23 (1.35) | 0.38 |
| TA | 287 (0.47) | 10.82 (0.48) | 209 (0.49) | 39.91 (1.32) | 71 (0.47) | 8.43 (1.15) | |||
| AA | 88 (0.15) | 9.22 (0.87) | 67 (0.16) | 40.93 (1.55) | 20 (0.13) | 10.09 (2.13) | |||
| missing | 11 (0.02) | 0 (0.00) | 0 (0.00) | ||||||
| rs7793837 | |||||||||
| AA | 349 (0.57) | 11.33 (0.44) | 0.05 | 235 (0.55) | 39.04 (1.23) | 0.24 | 75 (0.49) | 11.46 (1.08) | 0.03 |
| AT | 207 (0.34) | 10.07 (0.57) | 155 (0.36) | 41.98 (1.52) | 55 (0.36) | 7.34 (1.26) | |||
| TT | 40 (0.07) | 9.62 (1.29) | 31 (0.07) | 40.41 (3.40) | 8 (0.05) | 8.34 (3.35) | |||
| missing | 13 (0.02) | 6 (0.01) | *14 (0.09) | ||||||
| rs2284220 | |||||||||
| AA | 402 (0.66) | 10.82 (0.40) | 0.9 | 311 (0.73) | 41.08 (1.06) | 0.03 | 111 (0.73) | 9.34 (0.92) | 0.52 |
| AG | 141 (0.23) | 11.57 (0.68) | 103 (0.24) | 37.97 (1.84) | 27 (0.18) | 11.88 (1.91) | |||
| GG | 10 (0.02) | 6.67 (2.69) | 5 (0.01) | 20.86 (8.40) | 5 (0.03) | 8.07 (4.37) | |||
| missing | 54 (0.09) | 8 (0.02) | 9 (0.06) | ||||||
| rs2267716 | |||||||||
| TT | 361 (0.60) | 11.23 (0.43) | 0.1 | 246 (0.58) | 40.04 (1.22) | 0.84 | 82 (0.54) | 11.34 (1.11) | 0.05 |
| TC | 203 (0.33) | 10.09 (0.57) | 151 (0.35) | 41.25 (1.56) | 53 (0.35) | 7.11 (1.38) | |||
| CC | 33 (0.05) | 9.91 (1.41) | 26 (0.06) | 38.83 (3.78) | 5 (0.03) | 10.43 (4.71) | |||
| missing | 10 (0.02) | 4 (0.01) | *12 (0.08) | ||||||
rs # - refSNP number, count – genotype count, freq – frequency, means (se) –means bronchodilator response estimate obtained from linear regression (standard error), p – p-value obtained from linear regression under an additive model, CAMP – Childhood Asthma Management Program, LODO – Low Dose of Theophylline and Montelukast trial. Only variants with significant association (p-value ≤ 0.05) in at least 1 cohort are shown.
The mean bronchodilator response of subjects with missing genotypes is similar to the mean of those with genotypes (10.10% for rs7793837 and 9.46% for rs2267716 versus 9.68%); hence data can be considered missing at random.